J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's Victrelis is still likely to have a marketing advantage of one to two months over J&J's Incivek in the EU hepatitis C market, but pricing and reimbursement issues in the Member States will probably drive market share more than anything else.
You may also be interested in...
Merck Victrelis Glowing Recommendation From NICE At Odds With IQWiG
The contrasting views in Germany and England for the hepatitis C product underscore the difference between IQWiG’s purely scientific assessment and NICE’s focus on cost-effectiveness.
Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.
Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.